These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Vaccination: a new option to reduce the burden of herpes zoster. Mick G. Expert Rev Vaccines; 2010 Mar; 9(3 Suppl):31-5. PubMed ID: 20192716 [Abstract] [Full Text] [Related]
8. Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Sanford M, Keating GM. Drugs Aging; 2010 Feb 01; 27(2):159-76. PubMed ID: 20104941 [Abstract] [Full Text] [Related]
12. Herpes zoster vaccine: clinical trial evidence and implications for medical practice. Burke MS. J Am Osteopath Assoc; 2007 Mar 01; 107(3 Suppl 1):S14-8. PubMed ID: 17488883 [Abstract] [Full Text] [Related]
13. [Active immunoprophylaxis to reduce clinical impact of Herpes Zoster and its complications]. Marino MG, Bagnato B, Torella I, Franco E. Ig Sanita Pubbl; 2009 Mar 01; 65(3):299-311. PubMed ID: 19629155 [Abstract] [Full Text] [Related]
18. The effect of vaccination on the epidemiology of varicella zoster virus. Edmunds WJ, Brisson M. J Infect; 2002 May 01; 44(4):211-9. PubMed ID: 12099726 [Abstract] [Full Text] [Related]
20. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Hornberger J, Robertus K. Ann Intern Med; 2006 Sep 05; 145(5):317-25. PubMed ID: 16954357 [Abstract] [Full Text] [Related] Page: [Next] [New Search]